港股異動 | 貝康醫療-B漲7.58% 擬發行A股在科創板上市
格隆匯1月12日丨貝康醫療-B漲7.58%,報5.11港元創近半年新高,近三個交易日累計漲幅達32%,最新總市值14億港元。貝康醫療昨日盤後宣佈,為優化公司資本結構,提升自我發展能力及實現戰略發展目標,董事會決議於上海證券交易所科創板首次公開發售公司普通股並於以人民幣買賣。貝康醫療表示將展開相關籌備工作,但目前尚未制定建議A股發售的發售方案或釐定架構,亦未向相關監管機構提出申請,有關計劃須待董事會及股東正式批准,以及中國證監會與其他相關監管機構批准後方可作實。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.